These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 10532096)

  • 1. [Increased apoptosis of peripheral blood leukocytes correlates with leukopenia after high-dose chemotherapy].
    Chukhlovin AB
    Vopr Onkol; 1999; 45(4):384-6. PubMed ID: 10532096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma.
    Huijgens PC; Dekker-Van Roessel HM; Jonkhoff AR; Admiraal GC; Zweegman S; Schuurhuis GJ; Ossenkoppele GJ
    Bone Marrow Transplant; 2001 May; 27(9):925-31. PubMed ID: 11436102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
    Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
    Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Use of automatic blood analyzer, Hemalog D, in cancer patients during radiotherapy and chemotherapy].
    Zubrikhina GN; Manakhova LIu; Solov'eva EA; Lebedeva NB; Khaĭretdinova ZKh; Kachalov VK; Lebedev AI
    Vopr Onkol; 1990; 36(1):81-5. PubMed ID: 2305569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant.
    Oberlin O; Rey A; Desfachelles AS; Philip T; Plantaz D; Schmitt C; Plouvier E; Lejars O; Rubie H; Terrier P; Michon J;
    J Clin Oncol; 2006 Aug; 24(24):3997-4002. PubMed ID: 16921053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose carboplatin, cyclophosphamide, etoposide with hematological growth factors, without stem cell support in patients with advanced cancer.
    Recchia F; De Fillipis S; Piccinini M; Rea S
    Anticancer Res; 2003; 23(5b):4141-7. PubMed ID: 14666615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorouracil induces apoptosis and surface molecule modulation of peripheral blood leukocytes.
    Kimhi O; Drucker L; Neumann A; Shapiro H; Shapira J; Yarkoni S; Lahav M; Radnay J; Lishner M
    Clin Lab Haematol; 2004 Oct; 26(5):327-33. PubMed ID: 15485462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive cyclic chemotherapy with unprocessed whole blood support in advanced breast cancer.
    Vanásek J; Filip S; Medková V; Bláha M; Maricka P; Stránský P; Vavrová J
    Neoplasma; 2001; 48(1):34-8. PubMed ID: 11327535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.
    Anagnostopoulos A; Aleman A; Ayers G; Donato M; Champlin R; Weber D; Alexanian R; Giralt S
    Cancer; 2004 Jun; 100(12):2607-12. PubMed ID: 15197803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variations in the content of CD34+ cells in the peripheral blood of cancer patients receiving out-patient chemotherapy.
    Waller EK; Barlett N; Chen CH; Mujic V; Sussman H; Toepker S; Grenier K
    Cytotherapy; 1999; 1(1):21-9. PubMed ID: 19746646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Middle-high dose of cyclophosphamide or conventional routine chemotherapy with increased dose of cyclophosphamide combined with G-CSF for mobilizing peripheral blood progenitor cells in patients with tumor].
    Lu DP; Liu KY; Guo NL; Shi YK; He XH; Lou FD; Da WM; Zhang BL; Wang LX; Ke XY
    Zhonghua Xue Ye Xue Za Zhi; 2003 Feb; 24(2):68-70. PubMed ID: 12697098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of the in vivo effects of cladribine alone and its combination with cyclophosphamide or cyclophosphamide and mitoxantrone on Bax and Bcl-2 protein expression in B-CLL cells.
    Kobylinska A; Blonski JZ; Hanausek M; Walaszek Z; Robak T; Kilianska ZM
    Oncol Rep; 2004 Mar; 11(3):699-705. PubMed ID: 14767525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).
    Bouligand J; Boland I; Valteau-Couanet D; Deroussent A; Kalifa C; Hartmann O; Vassal G
    Bone Marrow Transplant; 2003 Nov; 32(10):979-86. PubMed ID: 14595385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relation between soluble apoptotic proteins and subclinical cardiotoxicity in adjuvant-treated breast cancer patients.
    Perik PJ; De Vries EG; Boomsma F; Messerschmidt J; Van Veldhuisen DJ; Sleijfer DT; Gietema JA; Van der Graaf WT
    Anticancer Res; 2006; 26(5B):3803-11. PubMed ID: 17094405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy.
    Kushner BH; Cheung IY; Kramer K; Modak S; Cheung NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):430-4. PubMed ID: 16421906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
    Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation.
    Schröder CP; Wisman GB; de Jong S; van der Graaf WT; Ruiters MH; Mulder NH; de Leij LF; van der Zee AG; de Vries EG
    Br J Cancer; 2001 May; 84(10):1348-53. PubMed ID: 11355946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated plasma ferritin and busulfan pharmacodynamics during high-dose chemotherapy regimens in children with malignant solid tumors.
    Bouligand J; Le Maitre A; Valteau-Couanet D; Grill J; Drouard-Troalen L; Paci A; Hartmann O; Benhamou E; Vassal G
    Clin Pharmacol Ther; 2007 Oct; 82(4):402-9. PubMed ID: 17392724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation.
    Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Chen HY; Mahmud N; Quigley J; Hoffman R; Jessop E; Beri R; Rondelli D
    Bone Marrow Transplant; 2006 Oct; 38(7):477-82. PubMed ID: 16980995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.